Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note issued to investors on Monday, MarketBeat reports. The brokerage set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s price target suggests a potential upside of 54.89% from the company’s previous close.

Several other research firms also recently commented on ORKA. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush started coverage on shares of Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price target for the company. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday. They issued a “buy” rating for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $41.25.

Oruka Therapeutics Stock Performance

ORKA stock opened at $26.47 on Monday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.